Hepatotoxicity with antituberculosis drugs: The risk factors

Pakistan Journal of Medical Sciences

Volumn 23, Issue 1, 2007, Pages 33-38

  Mahmood, Khalid ^a,b   Hussain, Akhtar ^a   Jairamani, Krishan Lal ^a   Talib, Abu ^a   Abbasi, Badar Uddin ^a   Salkeen, S ^a  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b NONE   (Pakistan)

Author keywords

Anti TB drugs; Hepatotoxicity; Risk factors; Tuberculosis

Indexed keywords

ALCOHOL; CHOLESTEROL; ETHAMBUTOL; ISONIAZID; PARACETAMOL; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ALCOHOL INTERACTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; HYPOCHOLESTEROLEMIA; LEAN BODY WEIGHT; LIVER FUNCTION; LIVER TOXICITY; LUNG TUBERCULOSIS; MALE; MORBIDITY; OPTIMAL DRUG DOSE; PAKISTAN; PATHOGENESIS; PATIENT MONITORING; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT;

EID: 33947132574     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Harries A, Maher D, Graham S. TB/HIV a clinical manual, second edition. World Health Organization, Geneva 2004;41-127.
2. Parasarthy, Raghupati, Sharma RG, Janardanam B, Ramachandran P, Santha T, et al. Hepatic toxicity in South Indian patient during treatment of TB with short course regimen containing INH, RMP and PZA. Tubercle 1986;67:69-108.
3. Koponoff DE, Snider DE Jr, Caras GJ. INH-related hepatitis: a US-public health service co-operative surveillance study. Am Respir Dis 1978;117(6):991-1001.
4. Garibaldi RA, Drusin RE, Ferebee SH, Gregg MB. INH-associated hepatitis; report of outbreak. Am rev Respir Dis 1972;106.
5. Timbrell JA, Park BK, Harland SJ. A study of the effects of RMP on INH metabolism in human volunteers. Hum Toxicol 1985;4:279-85.
6. Snider DE, Caras GJ. INH-associated hepatitis deaths: A review of available information. Am Rev Respir Dis 1992;145:494-7.
7. Omerod LP, Skinner C, Wales J. Hepatotoxicity of anti-TB drugs. Thorax 1996;51:111-3.
8. Hussain Z, Kar P, Husain SA. Anti Tuberculosis Induced Hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003;41(11):1226-32.
9. Tanaogllu K. The management of anti-TB drug-induced hepatotoxicity. The Int Union against Tuberculosis and Lung Disease 2001;5(1):65-9.
10. Ohno M, Yamaguchi I, Yamamoto I, Fukuda T, Yokota S, Maekura R, et al. Slow N-acetyltransferase 2 genotype affects the incidence of INH and RMP-induced hepatotoxicity. Intl J of Tuberc Lung Dis 2000;4(3):256-61.
11. Durand F, Bernuau J, Pessayre D, Samuel D, Deggott, Bismuth H, et al. Deliterous influence of PZA on the outcome of patient with fulminant or subfulminant liver failure during anti-TB treatment including INH. Hepatology 1995;21:929-32.
12. Villor AF, Sopena B, Villor JF. The influence of risk factors on the severity of antituberculosis drug induced hepatotoxicity: Int J Tuberc Lung disease 2004;8(12):1499-1505.
13. Shakya R, Rao BS, Shrestha B. Evaluation of risk factors for atni tuberculosis drug induced hepatotoxicity in Nepalese population. Ann Pharmacother 2004; 38(6):1074-9.
14. Yi-Shin Huang, Herng-Der Chern, Wei Juin Su, Jaw-Ching Wu, Shinn-Liang Lai, Shi-Yi Yang et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for all antituberculosis drugs-induced hepatitis. Hepatology 2002;35:883-9.
15. Steele MA, Burk RF, DesPrez RM. Hepatitis with INH and RMP: a meta-analysis. Chest 1991; 99:465-71
16. Mitchell JR, Jimmerman HJ, Ishak KG, Timbrell JA, Snodgrass WR, Nelson SD. INH-induced liver injury; Clinical spectrum, pathology, and possible pathogenesis. Ann Intern Med 1978;84:181-92.
17. Dorteh S, Askgaard DS. TB chemotherapy: The need for new drugs. Hepatotoxicity caused by the combined action of INH and RMP. Thorax 1995;60:213-14
18. Obrien RJ. hepatotoxic reaction due to anti-TB drugs: adjustment to therapeutic regimen. JAMA 1991; 265, 3323
19. Marvin W. Impacts of gender on drug responses. Drug Topics 1998;591-600.
20. Ungo JR, Jones D, Askin D. Anti-TB drugs-related hepatotoxicity; the role of hepatitis C &the human immuno-deficiency virus. Am J Respir Crit Care Med 1998;157:1871-6.
21. Singh J, Arora A, Garg PK, Thakur VS, Pande JN, Tandon RK. Anti-TB treatment induced hepatotoxicity: role of predictive factorrs. Postgrad Med J 1995; 71:359-62.
22. Gronhagen RC, Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by INH-RMP treatment of TB. Am Rev Respir Dis 1978;118(3):461-166.
23. Mehta S. Malnutrition and drugs: Clinical implications. Dev Pharmacol Ther 1990;15(3-4):159-65.
24. Micheal T, Lawrence S, Friedman. Hepatotoxicity of antibiotics and anti fungals: Drug Hepatotoxicity, clinics in liver diseases 2003;7(2):381-99.
25. Dossing M, Wilche J, Askgaard DS, Nybo B. Liver injury during anti-TB therapy. 11-year study. Tuber Lung Dis 1996;77(4):335-40.
26. Altman C, Biour M, Grange J. Hepatotoxicity of antitubercular agents: Role of different drugs. Presse Med 1993;22(26):1212-6.
27. Pande JN, Sing SP, Khilnani GC, Khilnani, Tandon RK. Risk factors for hepatotoxicity from anti-TB drugs; a case control study. Thorax 1996;51:1326.
28. Yossef AV, Gay, Sobouti R. Cholesterol is accumulated by mycobacteria but its degredation is limited to non pathogenic fast growing mycobacteria. Can J Microbiol 2000;46:826-31.
29. Singh J, Garg PK. Thakur VS, Tandon RK. Anti-TB treatment induced hepatotoxicity: Does acetylator status matters. Indian J Physiol Pharmacol 1995;39(1):43-6.
30. Corbella X, Vadillo M, Cabellos C. Hypersensitivity hepatitis due to Pyrazinamide. Scand J Infect Dis 1995;27:93-4.